[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Eye Institute of West Florida\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100642690","lacrifill-for-ocular-surface-optimization-in-cataract-surgery-100642690",false,"NCT07648095","Lacrifill for Ocular Surface Optimization in Cataract Surgery","Evaluation of Lacrifill™ Canalicular Filler for Optimization of Ocular Surface Parameters and Biometric Precision in Prospective Cataract Surgery Patients With Dry Eye Disease","Inclusion Criteria:\n\n* Age \\>= 40 years\n* Diagnosed dry eye (OSDI \\>= 13, TBUT \\\u003C 10 sec, or Oxford staining \\>= Grade 2)\n* No recent ocular surgeries (\\\u003C6 months)\n* No significant changes in DED regimen within last 1 month\n\nExclusion Criteria:\n\n* Previous punctal plugs or canalicular cautery\n* Active ocular inflammation or corneal pathology unrelated to DED","ALL","40 Years",{"count":19,"type":20},65,"ESTIMATED","OBSERVATIONAL","This is a single-site observational study designed to evaluate the efficacy of Lacrifill™ canalicular filler in optimizing ocular surface parameters and biometric precision in prospective cataract surgery patients with dry eye disease (DED).",[24],"Cataract","NOT_YET_RECRUITING","2026-06-12",{"date":28,"type":29},"2026-06-15","ACTUAL",{"date":31,"type":20},"2026-07-15",{"date":33,"type":20},"2027-07-15",{"name":35,"class":36},"The Eye Institute of West Florida","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":47,"conditions":48,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":37},"100622997","dslt-for-reducing-medication-in-glaucoma-100622997","NCT07390890","DSLT for Reducing Medication in Glaucoma","Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Medication Burden in Medically Controlled Patients With Ocular Hypertension or Primary Open Angle Glaucoma","Inclusion Criteria:\n\n* Adult patients scheduled to undergo DSLT treatment in one or both eyes.\n\n  * Diagnosis of ocular hypertension or primary open angle glaucoma (POAG).\n* Medically controlled on 1-3 topical ocular hypotensive agents with IOP ≤21 mmHg.\n\nExclusion Criteria:\n\n* Previous glaucoma surgeries\u002Finterventions:\n\n  * Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt).\n* Patients who have undergone cataract surgery within the prior 2 years.\n* Secondary glaucoma:\n\n  * Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases.\n* Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator.",{"count":46,"type":20},60,"This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma.\n\nThe study will assess the primary endpoint of reduction in medication count at 6 months compared to baseline. Secondary endpoints include IOP reduction compared to baseline (both percentage and absolute), complete success rate (no increase in IOP without medications), proportion of eyes needing medication at 6 months, and any secondary surgical interventions at 6 months post-DSLT.\n\nParticipants will undergo DSLT with 120 shots, 400 µm spot size, and 1.8mJ fixed energy delivered at the limbus over 2.4 seconds. Follow-up visits will occur at 1 month, 3 months, and 6 months post-procedure, with IOP measured using a calibrated Goldmann tonometer.",[49,50],"Primary Open Angle Glaucoma","Ocular Hypertension","RECRUITING","2026-04-17",{"date":54,"type":29},"2026-04-20",{"date":56,"type":29},"2026-02-10",{"date":58,"type":20},"2027-01-26",{"name":35,"class":36},""]